{"title":"3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening.","authors":"Hani Keshavarz Alikhani, Fatemeh Majidi, Mahsa Ghasemzad, Anastasia Shpichka, Anastasia Nestorova, Zahra Hendi, Elham Rismani, Daria Kuznetsova, Peter Timashev, Massoud Vosough, Abbas Piryaei","doi":"10.1002/prp2.70306","DOIUrl":null,"url":null,"abstract":"<p><p>Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown. There are many key players involved in the initiation and progression of liver fibrosis. Thus, the specific type of underlying disease and the study's objectives should be considered while choosing suitable models for liver fibrosis. Numerous in vitro and in vivo models have been generated to investigate liver fibrosis and proposed for drug screening and toxicology; however, there are no ideal in vitro models for drug discovery yet. In this review, we introduced the available in vitro models and highlighted certain platforms such as organoids and liver-on-a-chip for investigating liver fibrosis. Furthermore, we discussed the current challenges and potential application of each model.</p>","PeriodicalId":19948,"journal":{"name":"Pharmacology Research & Perspectives","volume":"14 4","pages":"e70306"},"PeriodicalIF":2.6000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13428035/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Research & Perspectives","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/prp2.70306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown. There are many key players involved in the initiation and progression of liver fibrosis. Thus, the specific type of underlying disease and the study's objectives should be considered while choosing suitable models for liver fibrosis. Numerous in vitro and in vivo models have been generated to investigate liver fibrosis and proposed for drug screening and toxicology; however, there are no ideal in vitro models for drug discovery yet. In this review, we introduced the available in vitro models and highlighted certain platforms such as organoids and liver-on-a-chip for investigating liver fibrosis. Furthermore, we discussed the current challenges and potential application of each model.
期刊介绍:
PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS